Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
STOK 
Stoke Therapeutics Inc (STOK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: STOK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -36.16% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 390.49M USD | Price to earnings Ratio - | 1Y Target Price 23.88 |
Price to earnings Ratio - | 1Y Target Price 23.88 | ||
Volume (30-day avg) 896798 | Beta 0.98 | 52 Weeks Range 6.10 - 17.58 | Updated Date 03/31/2025 |
52 Weeks Range 6.10 - 17.58 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.65 |
Earnings Date
Report Date 2025-03-24 | When Before Market | Estimate -0.5302 | Actual -0.18 |
Profitability
Profit Margin -243.42% | Operating Margin (TTM) -60.37% |
Management Effectiveness
Return on Assets (TTM) -25.35% | Return on Equity (TTM) -45.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 144499186 | Price to Sales(TTM) 10.68 |
Enterprise Value 144499186 | Price to Sales(TTM) 10.68 | ||
Enterprise Value to Revenue 3.95 | Enterprise Value to EBITDA -3.62 | Shares Outstanding 54077700 | Shares Floating 37144917 |
Shares Outstanding 54077700 | Shares Floating 37144917 | ||
Percent Insiders 4.82 | Percent Institutions 108.25 |
Analyst Ratings
Rating 4.6 | Target Price 22.75 | Buy 2 | Strong Buy 7 |
Buy 2 | Strong Buy 7 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Stoke Therapeutics Inc
Company Overview
History and Background
Stoke Therapeutics Inc. was founded in 2014 and is based in Bedford, Massachusetts. The company focuses on developing antisense oligonucleotide (ASO) medicines to treat severe genetic diseases by upregulating protein expression.
Core Business Areas
- Genetic Disease Treatment: Stoke develops antisense oligonucleotides (ASOs) aimed at increasing protein production from healthy genes to compensate for the effects of disease-causing mutations. They primarily focus on haploinsufficiencies.
Leadership and Structure
Stoke Therapeutics is led by CEO Edward M. Kaye, MD. The company has a board of directors with members from venture capital and pharmaceutical backgrounds. The organizational structure is typical for a biotechnology company, with research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- STK-001 ( Dravet Syndrome): STK-001 is an antisense oligonucleotide (ASO) in clinical development for the treatment of Dravet syndrome. It aims to upregulate the expression of the SCN1A gene. The competitors are gene therapies such as PTC Therapeutics, Encoded Therapeutics, Xenon Pharmaceuticals Inc.
Market Dynamics
Industry Overview
The industry is biotechnology, with a focus on genetic medicine. Key trends include advances in gene therapy, RNA therapeutics, and precision medicine.
Positioning
Stoke Therapeutics is a clinical-stage biotechnology company focused on developing antisense oligonucleotide (ASO) medicines to treat severe genetic diseases. They are a key player in the ASO therapeutics area.
Total Addressable Market (TAM)
The estimated total addressable market (TAM) for genetic disease therapies is very broad and is expected to be over $100 Billion, depending on specific indications and regulatory approvals. Stoke is targeting specific segments of this market, such as Dravet Syndrome, with the goal of expanding into other genetic diseases. Stoke's positioning is as an innovator in addressing genetic diseases that have been difficult to treat.
Upturn SWOT Analysis
Strengths
- Proprietary TANGO platform for ASO development
- Focus on genetically defined diseases
- Experienced leadership team
- Strong intellectual property position
Weaknesses
- Clinical trial risks and uncertainties
- Dependence on successful development of STK-001
- Limited commercialization experience
- High cash burn rate
Opportunities
- Expanding the pipeline to other genetic diseases
- Partnerships with larger pharmaceutical companies
- Advancements in ASO delivery technologies
- Favorable regulatory environment for orphan drugs
Threats
- Competition from other biotechnology companies
- Regulatory hurdles
- Patent challenges
- Unfavorable clinical trial outcomes
Competitors and Market Share
Key Competitors
- IONS
- PTCT
- AGEN
Competitive Landscape
Stoke's competitive advantage lies in its proprietary ASO technology platform and focus on upregulating gene expression. Competitors include companies developing other ASOs, gene therapies, and small molecule drugs for genetic diseases. Stoke's ability to differentiate its approach in terms of safety, efficacy, and delivery will be crucial for success.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the advancement of its clinical pipeline, particularly STK-001, and strategic partnerships. Stoke's growth is tied to successfully navigating the drug development process.
Future Projections: Future growth projections depend on the success of ongoing clinical trials and the expansion of its pipeline. Analyst estimates vary based on the likelihood of STK-001's approval and commercial success.
Recent Initiatives: Recent initiatives include enrolling patients in clinical trials for STK-001, presentations at scientific conferences, and exploration of new therapeutic targets using their TANGO platform.
Summary
Stoke Therapeutics is a clinical-stage biotech with a promising ASO platform. The success of STK-001 is crucial for its near-term valuation. It faces the inherent risks of drug development and needs to manage its cash burn effectively. Future expansion into other genetic diseases will be vital.
Similar Companies
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
IONS
Ionis Pharmaceuticals Inc
IONS
Ionis Pharmaceuticals Inc
PTCT
PTC Therapeutics Inc
PTCT
PTC Therapeutics Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Investor Presentations
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and is subject to change. Market share values are estimates and may not reflect actual figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Stoke Therapeutics Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 2019-06-19 | Interim CEO & Director Mr. Ian F. Smith A.C.A., C.P.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 128 | |
Full time employees 128 | |||
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in restoring protein expression by harnessing the body's potential with RNA medicine. The company utilizes its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome, and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.